Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease

MLA

Jeannie K. Lee, et al. “Health Outcomes and Cost-Effectiveness of Certolizumab Pegol in the Treatment of Crohn’s Disease.” Expert Review of Pharmacoeconomicsoutcomes Research, vol. 14, no. 5, Sept. 2014. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8053b33fe6d0e3a399bebdf8b0b98bff&authtype=sso&custid=ns315887.

APA

Jeannie K. Lee, Edward P. Armstrong, & Jill Augustine. (2014). Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn’s disease. Expert Review of Pharmacoeconomicsoutcomes Research, 14(5).

Chicago

Jeannie K. Lee, Edward P. Armstrong, and Jill Augustine. 2014. “Health Outcomes and Cost-Effectiveness of Certolizumab Pegol in the Treatment of Crohn’s Disease.” Expert Review of Pharmacoeconomicsoutcomes Research 14 (5). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....8053b33fe6d0e3a399bebdf8b0b98bff&authtype=sso&custid=ns315887.